Drug intelligence / Profile preview

granatin B

Development stage
Preclinical
Lead developer
Lin BioScience
Modality
Small Molecules
Administration
Oral
01

Overview

Granatin B is a hydrolyzable ellagitannin belonging to the dehydrohexahydroxydiphenoyl (DHHDP) group, primarily isolated from the leaves of *Acer pseudosieboldianum* (Korean flowering maple) and the fruit of *Punica granatum* (pomegranate). It is recognized for its potent chemopreventive and antineoplastic activities, particularly in the context of prostate cancer. The compound functions as an epigenetic modulator by inhibiting the activity of DNA methyltransferases, including DNMT1, DNMT3a, and DNMT3b. This inhibition facilitates the demethylation and subsequent re-expression of silenced genes, such as glutathione S-transferase P1 (GSTP1), which is often hypermethylated during prostate cancer progression. Beyond its epigenetic effects, granatin B exhibits anti-proliferative and apoptosis-promoting properties in various cancer cell lines.

02

Targets

DNMT3A (DNA methyltransferase 3 alpha)DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)

Beyond the preview

Go deeper on granatin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on granatin B.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call